Longeveron appoints Dr. Nataliya Agafonova as CMO, effective July 1, 2023

Longeveron Inc.

Dr. Agafonova replaces Dr. K. Chris Min, who stepped down as CMO on June 30, 2023.
She will lead global clinical development and regulatory strategy.
Agafonova previously served as Clinical Development Lead at Otsuka Pharmaceutical and Bristol-Myers Squibb.
A consulting agreement with hourly cash fee is in place until full-time employment begins on or about July 24, 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

K. Chris Min

Chief Medical Officer

LGVN · Longeveron Inc.

Effective: 2023-06-30
Successor: Nataliya Agafonova
Filed: July 5, 2023, 7:59 PM ET

Dr. K. Chris Min, the Company’s prior CMO, stepped down effective June 30, 2023.

Appointed

Nataliya Agafonova

Chief Medical Officer

LGVN · Longeveron Inc.

Effective: 2023-07-01
Filed: July 5, 2023, 7:59 PM ET

Longeveron Inc. (“Longeveron” or the “Company”) has announced the appointment of Dr. Nataliya Agafonova M.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (“CMO”), effective July 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

K. Chris Min departed as Chief Medical Officer at Longeveron Inc..

Action: stepped down
Role: Chief Medical Officer

Exact text from the filing

Dr. K. Chris Min, the Company’s prior CMO, stepped down effective June 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nataliya Agafonova was appointed as Chief Medical Officer at Longeveron Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Longeveron Inc. (“Longeveron” or the “Company”) has announced the appointment of Dr. Nataliya Agafonova M.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (“CMO”), effective July 1, 2023.

View on SEC.gov

Longeveron Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-054758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.